Clinical trials: Complication of Infusion
Fanconi Anemia Complementation Group A, Fanconi Anemia
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
This is a long-term safety and efficacy follow-up study for subjects with Fanconi Anaemia Subtype A who have been treated with ex vivo gene therapy on the FANCOLEN-I trial.
- Trial name
- NCT04437771
- Testing
- Safety and efficacy assessments
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- Rocket Pharmaceuticals Inc.
Colorectal Cancer, Breast Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in…
- Conditions
- Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer
- Trial name
- NCT04640480
- Testing
- SNB-101
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- SN BioScience
Fatigue, End Stage Renal Disease (ESRD)
Lipid Infusion in Dialysis Patients With Endotoxemia
The purpose of this study is to determine whether a phospholipid emulsion is effective in the treatment of chronic endotoxemia in hemodialysis patients.
- Trial name
- LIPIDOSE (NCT00506454)
- Testing
- Lipidose
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sepsicure
Immunoglobulin A Nephropathy (IgAN)
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time.
- Trial name
- PREVAIL (NCT06935357)
- Testing
- Felzartamab
- Where
- 265 sites in United States, Argentina and 26 more
- Volunteers
- 454 people
- Sponsor
- Biogen
Renal Impairment
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects
This is an open-label, non-randomized, single-center, single i.v. dose Phase 1 trial to evaluate the pharmacokinetics and safety of a combination of ANT3310 and meropenem in participants with different degrees of renal function…
- Trial name
- NCT06527677
- Testing
- ANT3310, Meropenem
- Where
- Germany
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Antabio
Renal Insufficiency, Chronic
Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease
A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients with End Stage Renal Disease (ESRD).
- Trial name
- NCT02437422
- Testing
- SANGUINATE
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Prolong Pharmaceuticals
Infusion Site Injury
Study to Estimate the Point Prevalence of Peripheral Intravenous Catheter-related Complications in Brazil
A multi-center, national prevalence study where: (1) baseline SPIVC therapy complications of hospitalized adult patients that meet the inclusion/exclusion criteria of the study and (2) the compliance of clinicians to the…
- Trial name
- PIVS (NCT03719287)
- Where
- 3 sites in Brazil
- Volunteers
- 295 people
- Sponsor
- Solventum US LLC
Renal Impairment
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
To investigate the pharmacokinetics (PK) of rifabutin in subjects with renal impairment after single intravenous (IV) infusion of BV100
- Trial name
- NCT05086107
- Testing
- BV100
- Where
- Hungary
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- BioVersys AG
Renal Impairment
Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function
This is a Phase 1 study to assess the pharmacokinetics (PK) of IK-1001 (sodium sulfide) in healthy volunteers as well as in subjects with varying degrees of impaired renal function.
- Trial name
- NCT00879645
- Testing
- Sodium Sulfide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Neoplasms
Study of ADH-1 Given Intravenously to Patients With Solid Tumors
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00265057
- Testing
- ADH -1 (Exherin™)
- Where
- 3 sites in Italy, Switzerland
- Sponsor
- Adherex Technologies, Inc.
Fabry Disease
Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alfa administered intravenously every four weeks in adult Fabry patients who have…
- Trial name
- NCT03614234
- Testing
- pegunigalsidase alfa
- Where
- 14 sites in United States, Belgium and 5 more
- Volunteers
- 29 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Diabetic Ketoacidosis
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
A number of scientific papers have been published on the efficacy and safety of adding REAMBERIN® (meglumin sodium succinate), a 1.5% infusion solution, to standard therapy for patients with diabetic ketoacidosis (DKA), which…
- Trial name
- NCT06955416
- Testing
- Reamberin
- Where
- 3 sites in Russia
- Volunteers
- 312 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Pain, Postoperative
Safety and Efficacy Study of KAI-1678 to Treat Subjects With Postoperative Pain
The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postoperative pain following total hip or total knee replacement.
- Trial name
- NCT01015235
- Testing
- KAI-1678, Ketorolac Tromethamine
- Where
- New Zealand
- Volunteers
- 90 people
- Sponsor
- KAI Pharmaceuticals